We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Salutary Tale-Glargine insulin and cancer risk.
- Authors
Boyle, Peter
- Abstract
The article reports on four articles published on "Diabetologia" journal on June 26, 2009 demonstrating the risk of cancer among patients treated with glargine insulin for type II diabetes. The European Union authorised insulin glargine as Lantus and Optisulin for treatment of diabetes in adults, adolescents and children aged six years or above. The European Medicines Agency's Committee for Medicinal Products for Human Use concludes the studies with no cause for concern and no changes required.
- Subjects
INSULIN; CANCER risk factors; TYPE 2 diabetes treatment; EUROPEAN Union; EUROPEAN Medicines Agency. Committee for Medicinal Products for Human Use
- Publication
Ecancermedicalscience, 2009, Vol 3, Issue 4-5, p1
- ISSN
1754-6605
- Publication type
Article
- DOI
10.3332/ecancer.2009.ed5